LIMNHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 8 Oct 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Liminatus Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (96): Smaller than most of the companies we track.
Growth (10): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LIMN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LIMN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Liminatus Pharma, Inc. returned −95.4% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 93% of US stocks
Cheaper than 7% of US stocks
Cheaper than 67% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 96% of US stocks
Higher than 3% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Liminatus Pharma, Inc. has a market value of $5.2M and an enterprise value of $3.4M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$12.5M.
Free cash flow in the twelve months to 30 June 2026: −$4.0M.
Trailing P/E: −9.0×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Liminatus Pharma, Inc. employs 1 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Liminatus Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Liminatus Pharma, Inc. announced on September 29, 2026 that it has regained compliance with Nasdaq's minimum bid price rule. The company made the announcement from its headquarters in Fullerton, California.
Why it matters — Regaining compliance with Nasdaq's minimum bid price rule removes a potential delisting risk for Liminatus Pharma's shares.
Liminatus Pharma announced it has engaged Synex Consulting Ltd. as a contract research organization to support the Phase 1/2a clinical development of its CD19xCD22 bivalent CAR-T therapy. The announcement was made via GlobeNewsWire on Aug. 24, 2026.
Why it matters — LIMN watchers would care because engaging a CRO signals progress toward advancing the company's lead CAR-T candidate into clinical trials.
Liminatus Pharma, Inc. announced that its board of directors adopted resolutions approving a 1-for-50 reverse stock split of its common stock. The split was approved by stockholders at the Company's 2026 Annual Meeting of Stockholders held on August 3, 2026.
Why it matters — A 1-for-50 reverse stock split will consolidate the number of outstanding shares and correspondingly adjust the per-share price of LIMN common stock, a significant corporate action for shareholders to track.
Liminatus Pharma announced that its common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026, and that the Nasdaq Hearings Panel granted the Company additional time to demonstrate compliance with Nasdaq's minimum bid price requirement.
Why it matters — This update is relevant to LIMN watchers because it addresses the Company's continued Nasdaq listing status and its bid price compliance timeline.
As at 8 Oct 2026, Liminatus Pharma, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).
No analyst covering Liminatus Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LIMN are extrapolating price history, which says nothing about the business.
Liminatus Pharma, Inc. returned -95.4% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies for cancer.
The most recent item we track (GlobeNewsWire, 29 Sept 2026): "Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule". Liminatus Pharma, Inc. announced on September 29, 2026 that it has regained compliance with Nasdaq's minimum bid price rule. The company made the announcement from its headquarters in Fullerton, California.
Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies for cancer. The company’s current work centers on immune-modulating treatments designed to address solid tumors, with a particular emphasis on CD47-blockade technology and its candidate IBA101, a humanized anti-CD47 monoclonal antibody. Liminatus Pharma is also associated with broader oncology research efforts that explore next-generation immune-based approaches and CAR-T platforms for difficult-to-treat cancers. Its business is concentrated in the biotechnology and healthcare sectors, where it contributes to the development of targeted cancer therapies intended to expand treatment options in oncology. Founded in 2018 and headquartered in California, Liminatus Pharma remains focused on advancing clinical research and therapeutic development for patients with unmet needs in cancer care.
CEO Mr. Chris Kim J.D., L.L.M. · 1 employees · United States · https://liminatuspharma.com
